Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CeriBell, Inc. (Nasdaq: CBLL) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a medical technology company focused on point-of-care electroencephalography (EEG) for serious neurological conditions, CeriBell uses its filings to report financial performance, material agreements, intellectual property actions, and key product milestones related to the Ceribell System.
Investors can review periodic reports and current reports on Form 8-K that describe quarterly financial results, including separate disclosure of product revenue and subscription revenue, as well as updates on cash, marketable securities, and operating expenses. Filings also cover material definitive agreements, such as the Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University for patent rights related to portable brain wave devices, and the Corporate Supply Agreement with Shenzhen Everwin Precision Technology Co., Ltd. and affiliates for EEG headband supply and related licenses.
Other 8-K filings document regulatory and legal developments, including announcements of FDA 510(k) clearance for the Clarity® algorithm in neonatal seizure detection, clearance for the company’s delirium monitoring solution, and the FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor. Filings also describe patent infringement complaints filed against Natus Medical Incorporated and related subsidiaries, as well as lease amendments for office space in Sunnyvale, California and governance changes such as the election of new directors.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand financial trends, material contracts, regulatory events, and intellectual property issues affecting CBLL. Users can also track insider-related disclosures when available through forms such as Form 4, and refer to annual reports on Form 10-K and quarterly reports on Form 10-Q for deeper insight into CeriBell’s business, risk factors, and operations.
Ceribell, Inc. President, CEO and director Xingjuan (Jane) Chao reported a series of planned stock transactions on February 4, 2026 under a Rule 10b5-1 trading plan adopted on September 12, 2025. She sold 14,000 shares of common stock at a weighted average price of $20.16, with individual sale prices ranging from $19.87 to $20.61.
On the same date she exercised stock options for 1,446 shares and 23,554 shares at an exercise price of $4.70 per share and sold the same numbers of shares at a weighted average price of $20.16. Following these transactions, she beneficially owned 727,248 shares of Ceribell common stock directly and 369,088 shares indirectly through the ACP 2021 Trust, where she is a co‑trustee and disclaims beneficial ownership except to the extent of her pecuniary interest.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 3,928,666.28 shares of Ceribell Inc common stock, representing 10.6% of the class as of 12/31/2025. The filing identifies both FMR LLC and Abigail P. Johnson as reporting persons with sole dispositive power over these shares and no shared voting or dispositive power.
The shares are reported as held in the ordinary course of business and not for the purpose of changing or influencing control of Ceribell. One or more other persons have rights to dividends or sale proceeds, but no single other person has more than five percent of the outstanding common stock.
Ceribell, Inc. officer David Foehr reported option exercises and share sales in company stock. On February 3, 2026, he exercised options to buy 3,403 and 2,153 shares at $4.70 per share and then sold the same amounts at $20.00 per share under a prearranged Rule 10b5-1 trading plan.
After these transactions, Foehr directly owned 18,900 shares of Ceribell common stock and held stock options covering 59,598 and 57,445 shares. The option grant vests 25% on May 31, 2023, with the remainder vesting in 36 equal monthly installments.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported planned option exercises and share sales in company stock. On February 2, 2026, he exercised several stock options at prices of $2.24 and $4.70 per share and sold the resulting common shares at weighted average prices around $20.57, all under a pre‑established Rule 10b5‑1 trading plan adopted on May 28, 2025.
Following these transactions, Woo directly beneficially owned 167,617 shares of Ceribell common stock, which includes 300 shares acquired through the company’s employee stock purchase plan on January 30, 2026. He also continues to hold multiple stock options that remain outstanding, some of which are fully vested and currently exercisable and others that continue to vest monthly from April 1, 2023.
CBLL shareholder Xingjuan Chao has filed a Form 144 to sell 39,000 shares of common stock, with an aggregate market value of $799,890, through Fidelity Brokerage Services on NASDAQ around February 4, 2026. The notice shows these shares coming from stock option exercises dated April 30, 2018 and February 4, 2026.
Over the prior three months, the same shareholder reported CBLL common stock sales of 50,000 shares on November 21, 2025, 25,000 shares on December 1, 2025, 25,000 shares on December 4, 2025, and 79,000 shares on January 5, 2026, with disclosed gross proceeds for each transaction.
CBLL insider David J. Foehr has filed a Form 144 notice to sell common stock. The filing covers a planned sale of 5,556 CBLL common shares through Fidelity Brokerage Services, with an aggregate market value of
The filing states that 37,095,690 CBLL shares were outstanding. The shares to be sold were acquired via stock options granted on
Raymond Woo filed a notice to sell 11,112 common shares of CBLL under Rule 144. The planned sale, through Fidelity Brokerage Services on NASDAQ, has an aggregate market value of $231,129.60 and is targeted for approximately February 2, 2026.
The shares were acquired by exercising stock options on February 2, 2026 that were originally granted on July 7, 2021 and February 16, 2023, for 1,472 and 9,640 shares respectively, paid in cash. Over the past three months, Woo has sold 11,112 CBLL common shares on each of November 11, 2025, December 1, 2025, and January 2, 2026, for gross proceeds of $136,496.56, $184,424.30, and $235,228.09.
Josef Parvizi Trust, an entity associated with Ceribell director Josef Parvizi, sold 25,000 shares of Ceribell common stock on January 15, 2026 at a weighted average price of $22.94 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on August 18, 2025, meaning the trades were pre-arranged rather than discretionary on the trade date. After the sale, the Josef Parvizi Trust held 747,652 shares, while the Innovation ACP Trust held 907,911 shares and the ACP 2021 Trust held 369,088 shares, all reported as indirectly owned, with beneficial ownership disclaimed except to the extent of pecuniary interest.
A shareholder has filed a notice of proposed sale under Rule 144 for 25,000 shares of common stock, to be sold through Fidelity Brokerage Services LLC on NASDAQ around 01/15/2026. The filing lists an aggregate market value of $573,453.07 for these shares and states that there are 37,095,690 common shares outstanding.
The 25,000 shares to be sold were originally acquired as pre-IPO shares from the issuer on 08/29/2014 for cash. The document also reports that the Josef Parvizi Trust sold 25,000 common shares on 12/08/2025 for gross proceeds of $506,467.06 and another 25,000 common shares on 12/15/2025 for gross proceeds of $538,650.34.
Ceribell, Inc. insider activity: Chief Revenue Officer Joseph S. Manni reported a disposition of 660 shares of Ceribell common stock on November 20, 2025, at a price of $13.64 per share under transaction code "F." After this transaction, he beneficially owned 27,401 shares of common stock in direct ownership. A footnote explains that this total includes 300 shares previously acquired through the company’s Employee Stock Purchase Plan on July 31, 2025.
FAQ
What is the current stock price of CeriBell (CBLL)?
What is the market cap of CeriBell (CBLL)?
